These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36031100)

  • 1. Quantitative changes of lipoprotein(a) in chronic hepatitis C patients achieving a sustained virological response by direct-acting antivirals.
    Okumura T; Joshita S; Sugiura A; Ota M; Umemura T
    Clin Res Hepatol Gastroenterol; 2022 Oct; 46(8):102011. PubMed ID: 36031100
    [No Abstract]   [Full Text] [Related]  

  • 2. Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.
    Hézode C; Fourati S; Chevaliez S; Scoazec G; Soulier A; Varaut A; François M; Ruiz I; Roudot-Thoraval F; Mallat A; Pawlotsky JM
    Clin Infect Dis; 2017 Jun; 64(11):1615-1618. PubMed ID: 28369411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil.
    Holzmann I; Tovo CV; Minmé R; Leal MP; Kliemann MP; Ubirajara C; Aquino AA; Araujo B; Almeida PRL
    Braz J Infect Dis; 2018; 22(4):317-322. PubMed ID: 30036490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience of a Portuguese Center: Effectiveness of Direct-Acting Antiviral Therapy for Hepatitis C.
    Falcão F; Lopes C; Viegas E; Perez R; Aldir I; Farinha H; Carvalho A; Mirco A; Marques S; Bana E Costa T; Miranda AC; Lebre L; Peixe P; Chagas C; Mansinho K; Correia JM
    Acta Med Port; 2019 Mar; 32(3):189-194. PubMed ID: 30946789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is Sustained Virologic Response to Direct-acting Antivirals a Valid Surrogate Endpoint for Clinical Outcomes of Hepatitis C?
    Lok AS
    Clin Infect Dis; 2021 Mar; 72(5):787-788. PubMed ID: 32052046
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.
    Fabrizi F; Aghemo A; Lampertico P; Fraquelli M; Cresseri D; Moroni G; Passerini P; Donato FM; Messa P
    Int J Artif Organs; 2018 Jun; 41(6):306-318. PubMed ID: 29595085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents.
    Mashaal AR; Abd El-Hameed M; El Ray AA; Mahmoud Diab T; Dawood RM; Shemis MA; Seyam M
    Asian Pac J Cancer Prev; 2022 Sep; 23(9):2965-2971. PubMed ID: 36172658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors That Influence the Virological Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin.
    Todorovska B; Joksimovic N; Caloska-Ivanova V; Dimitrova-Genadieva M; Trajkovska M; Curakova E; Kiprijanovska S; Zafirova-Ivanovska B; Serafimoski V
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Mar; 38(1):25-33. PubMed ID: 28593897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals.
    van Tilborg M; Lieveld FI; Smolders EJ; van Erpecum KJ; de Kanter CTMM; Maan R; van der Valk M; Arends JE; Dofferhoff ASM; Blokzijl H; Bijmolen M; Drenth JPH; de Knegt RJ; Burger DM;
    Aliment Pharmacol Ther; 2017 Nov; 46(9):864-872. PubMed ID: 28881031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct-acting antivirals response in an acute nosocomial genotype 1b HCV outbreak.
    Benson AA; Wolf D; Lederman N; Safadi R
    Dig Liver Dis; 2018 Jun; 50(6):630-632. PubMed ID: 29628358
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
    Taneja S; Duseja A; De A; Kumar V; Ramachandran R; Sharma A; Dhiman RK; Gupta KL; Chawla Y
    Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment.
    Muñoz de Rueda P; Fuentes Rodríguez JM; Quiles Pérez R; Gila Medina A; Martín Álvarez AB; Casado Ruíz J; Ruíz Extremera A; Salmerón J
    World J Gastroenterol; 2017 Jul; 23(25):4538-4547. PubMed ID: 28740342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong.
    Hui YT; Wong GLH; Fung JYY; Chan HLY; Leung NWY; Liu SD; Liu K; Ma YK; But DYK; Mak WY; Chan JMC; Lai KB; Loo CK; Ng ACY; Lai MS; Chan CW; Lau JYL; Fan TTT; Hui AJ; Lam BCY; Cheung WI; Tsang OTY; Lam K; Lai LSW; Luk WF; Li MKK; Lao WC; Lam JTW; Tsang SWC; Kung KN; Chow WH; Tong RKN; Lui TKL; Shan EHS; Yuen MF; Wong VWS
    Liver Int; 2018 Nov; 38(11):1911-1919. PubMed ID: 29981176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
    García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
    Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of laboratory monitoring during hepatitis C treatment with ribavirin-free direct-acting antiviral regimens.
    VanOpdorp JR; Ferrentino N; Strader DB; Lidofsky SD
    J Viral Hepat; 2019 Jun; 26(6):778-781. PubMed ID: 30801878
    [No Abstract]   [Full Text] [Related]  

  • 16. Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
    Akuta N; Kobayashi M; Suzuki F; Sezaki H; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    Oncology; 2016; 91(6):341-347. PubMed ID: 27694754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation.
    Iacob S; Cerban R; Pietrareanu C; Ester C; Iacob R; Gheorghe C; Popescu I; Gheorghe L
    J Gastrointestin Liver Dis; 2018 Jun; 27(2):139-144. PubMed ID: 29922758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concordance of sustained virologic response at weeks 4, 12 and 24 post-treatment of hepatitis c in the era of new oral direct-acting antivirals: A concise review.
    Burgess SV; Hussaini T; Yoshida EM
    Ann Hepatol; 2016; 15(2):154-9. PubMed ID: 26845592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virological Response to Sofosbuvir-Based Treatment in Renal Transplant Recipients With Hepatitis C in Pakistan.
    Hanif FM; Mandhwani R; Lail G; Luck NH; Aziz T
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):198-201. PubMed ID: 30777554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct antiviral treatment of chronic hepatitis C in heart transplant recipients.
    Vitrone M; Andini R; Mattucci I; Maiello C; Atripaldi L; Durante-Mangoni E; Zampino R
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29139181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.